HSBC Lowers Repligen (NASDAQ:RGEN) Price Target to $150.00

Repligen (NASDAQ:RGEN) had its target price reduced by HSBC from $170.00 to $150.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HSBC’s price target would suggest a potential upside of 23.07% from the stock’s previous close.

Several other research analysts have also weighed in on RGEN. Royal Bank Of Canada initiated coverage on shares of Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research note on Tuesday, May 5th. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Wells Fargo & Company dropped their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group dropped their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Stock Up 0.6%

Repligen stock traded up $0.76 during trading hours on Wednesday, hitting $121.89. The company had a trading volume of 195,186 shares, compared to its average volume of 953,747. The firm has a market capitalization of $6.88 billion, a P/E ratio of 135.27, a price-to-earnings-growth ratio of 2.37 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The firm’s fifty day moving average is $118.05 and its 200-day moving average is $139.53. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $175.77.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, research analysts forecast that Repligen will post 1.99 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC lifted its stake in Repligen by 1.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after buying an additional 75 shares in the last quarter. NewEdge Wealth LLC lifted its position in shares of Repligen by 5.3% in the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 75 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Repligen by 13.8% in the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 92 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in shares of Repligen by 0.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after purchasing an additional 100 shares in the last quarter. Finally, Coldstream Capital Management Inc. lifted its position in shares of Repligen by 5.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 101 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.